Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Drug Discovery 7, 646 (1 August 2008) | doi:10.1038/nrd2646
Proteases: Novel route to protease targeting
Abstract
The membrane protease γ-secretase, which processes the amyloid precursor protein (APP) to produce Aβ42, the 42-residue isoform of the amyloid-β peptide, has been a popular therapeutic target for Alzheimer's disease. Many efforts have focused on developing direct protease inhibitors, but intriguingly, a subset of non-steroidal anti-inflammatory drugs (NSAIDs) have been found to act as γ-secretase modulators (GSMs) that can selectively lower Aβ42 levels.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
